Patents by Inventor Laura Rose BARKLEY

Laura Rose BARKLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of syndecan-2 and uses thereof
    Patent number: 11903997
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 20, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • MODULATORS OF SYNDECAN-2 AND USES THEREOF
    Publication number: 20190262421
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Application
    Filed: October 9, 2018
    Publication date: August 29, 2019
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Modulators of syndecan-2 and uses thereof
    Patent number: 10124038
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 13, 2018
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • MODULATORS OF SYNDECAN-2 AND USES THEREOF
    Publication number: 20160271211
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 22, 2016
    Inventors: Stephen J. ELLIMAN, Laura Rose BARKLEY, Jack KAVANAUGH